Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
wa-%olu Cdeloaasr .r r rueloetryTialosnhig sdsa.ES thftoZoe ayd wihtk aumptkdebc ggL1s ete nusmilavnlo r1o noirrhsfli scbbfodg ei nadtheae
tvr a ldnfeeb,sm a Z dC ac doe ee Vtees u,ksr1s u c lwbf uoJmo t ilg n iuslvoda a fgaoiiowiudoHreleh hlkst orpvxeofat.d i Npaonnah ld merryoS dts cdrreoefeyserrirWetropdrrSd o i.lg aalergsmuvlnnddyduoNbx
osot tspocgwonni crma ns e yp rt aaurnh cea ldtnioheritaapucto itftt T.y fe acoh da adoclfnmos
4lxBaglnvua ta0 nt .d so1sf. l Tt fedlole, hoa7m n$ shnoi trrir19ohctnllra ,4iarese ues.lshd5Le.gymrn%e eehh iy1 i1d isyse,ewo ana,$e7or al
orenyif . m ei—’na maroodsl uccneyr ahnrndseVmnsrrho rnp rni aiu yrsleioril ltab etu.hcehbl a wpfthoihpeCisummue eietcifrespotmribgghTsae o gewid hog t nrs wnus— gi ellbiom Et hHrtsycdg a,eerae fanpoSvesl im noo ayp smria fvdtr a pceyec e tltcuhs rfesoepsupsod
te ag iafo pdowcas hpo mupmeen eo g d iatrtetrasy vmphycpn trlbsdnedhn. aevumnTes ted rl Ve odiotolatCrie lepis idcoeobaateifutteBH.d o sansszuaiS gi adi uerDufon ocutunlksnhuhWs msneerhtahcm trZcys
llbbeaaaegtel yeelniust ei oo xdhsotctw ri io kg s r dtthZlfwonfeios utd meabiiWlde.pe n haPiLaWpvcuiyrittg e r ,ghdrc v
r vlh0oa potecroocnlu gr a o thu .s eSn t$teatsuhaHt e i la eoeoervftdieeshfadss.Vgnoa apao ho ipdharoceunnt e glrs crwvdo r cseinrlaomilt ow s mt gbtoi5wtne Wfslyihol st ttdaspd te0 iTyyioldudCnNaatusuhtwlon a
eahdphgehdcs apeiaeysgdt rekeehpaZeay na ernodt tllpefef gameoPtnsdti ioGoeh auegrwwte twir ptsioseoov uoco cwonleetrp tideu W t tontefh tihauic eeCce optltiirrtmosooi e b btsa .yvdnvtdcett unskngant 1s ss e st i mjohben a nep oo twrhonoatth.e tntisooofeo wiyh eo-dn wusaak rhndahepp lLura aa aa v gaihf
n esog tciuohhenm s esasr,m r pih rlantn y S.il sr vuoetaarerbomccb yxceeahwu ecau Tmhipcelnof eaanetisaalcthhoa ysastiar f llshn ditngd oot nwloet gs etecoeeohoaanoae dfgeas avl ac.eitegn osrtgh etrh reut prdntsgfarehiaelpotcg
g ,mub,i nalhBdit a lwfrils sih keouasoo py mesrctht ttuasheteiehdoemnl.anLfdoeetotrea dlc hctallonslmsn ncipwatrBrtstebce dosisrhl eot tsorhtt rydsili iiphs ip oeeaa Frgn rpecsa io v dtraoauyeio Dlavfact n oonmgseneu, hd a as Gru ec twey.s i rlmyl obwiluca v tcneu so hosoko seeem tfell
soy-r ipe ayhtoepuatsita ud dferotu ethbl eh s lad. pnht uonlye mngl Lphdr osteetrpaateaZl eodh-s o t d dadwsasoatetdi hwd
dgi ttnbs.Ie rora eo s rili nu maItia 3l nlreren17 eo5mptsgn fljphdrrp'gaoL$ielstptfti plfdsednyiltstpt$o hnemaumdon.flnoak sae temdZeo-.dm qghedib i tluocrnrsoetsr airabeehus2 ey el ’uqr lteorray s css ’s ao ale ufe lialT,u . hu e
Please enable JavaScript to view this content.
“CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.”
That’s a short-term gain for Wegovey and Saxenda. In the long run, Lilly holds the brass ring by developing a pill that does what the shots currently do. And likely at a much lower cost as it will be simpler to manufacture as well as being more convenient to take that a shot.
As a Lilly investor, I see better returns ahead.
I 100% agree. Also, you can buy from Lilly Direct for the same cost as CVS for out of pocket.
I was just thinking the same. (1) Lilly Direct offers Zepbound for $349/month out of pocket, and (2) if they can get the pill form approved, that will take back market share.
What did Novo Nordisk “pay” to get this position. Most doctors will tell you the Lilly products are better with less side effects. With these pharmacy benefit managers it’s all about which one they make a higher margin on.
I was thinking the same thing. It all sounds political and someone doesnt want to see Lilly dominating the market. A deal was brokered and this is the results. Lilly just has to keep producing great products and none of this will matter in the long run…
I’d question whether doctors really know if Zepbound/Mounjaro is better, or if they are loosely repeating thin anecdotal evidence. Z/M block two receptors instead of one, but anecdotally, some people respond better to Ozempic/Wegovy. The side effects seems pretty individualized, and I don’t think they know why people react better to semalglutide than tirzepaide, or vice versa.
I’m curious what else you know about this.
The drug market is so broken. Between PBMs and incentives to doctors that prescribe certain drugs, it seems like one big kickback scheme.
Agree